SG11201912864SA - Multi-specific antibodies and methods of making and using thereof - Google Patents
Multi-specific antibodies and methods of making and using thereofInfo
- Publication number
- SG11201912864SA SG11201912864SA SG11201912864SA SG11201912864SA SG11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA
- Authority
- SG
- Singapore
- Prior art keywords
- making
- methods
- specific antibodies
- antibodies
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762524557P | 2017-06-25 | 2017-06-25 | |
PCT/US2018/039156 WO2019005639A2 (en) | 2017-06-25 | 2018-06-22 | MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201912864SA true SG11201912864SA (en) | 2020-01-30 |
Family
ID=64742644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201912864SA SG11201912864SA (en) | 2017-06-25 | 2018-06-22 | Multi-specific antibodies and methods of making and using thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US11787863B2 (de) |
EP (1) | EP3645049A4 (de) |
JP (1) | JP7399852B2 (de) |
KR (1) | KR20200092301A (de) |
CN (4) | CN116041530A (de) |
AU (1) | AU2018295118A1 (de) |
CA (1) | CA3068045A1 (de) |
IL (2) | IL313468A (de) |
RU (1) | RU2020102662A (de) |
SG (1) | SG11201912864SA (de) |
WO (1) | WO2019005639A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3645738A4 (de) * | 2017-06-25 | 2021-08-18 | Systimmune, Inc. | Anti-pd-l1-antikörper und verfahren zu ihrer herstellung und verwendung |
CN110891650B (zh) * | 2017-06-25 | 2024-06-11 | 西雅图免疫公司 | 制导和导航控制蛋白及其制造和使用方法 |
US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
US12029761B2 (en) * | 2018-03-27 | 2024-07-09 | Systimmune, Inc. | Guidance and Navigation Control proteins and method of making and using thereof |
CN118459602A (zh) * | 2019-11-06 | 2024-08-09 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
US20240067741A1 (en) * | 2019-11-19 | 2024-02-29 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
EP3988568A1 (de) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Kombinationsbehandlung |
WO2023198635A1 (en) * | 2022-04-11 | 2023-10-19 | Astrazeneca Ab | T cell binding proteins |
WO2024137697A1 (en) * | 2022-12-20 | 2024-06-27 | Oncternal Therapeutics, Inc. | Combination therapies for the treatment of cancer |
WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
CN116143934B (zh) * | 2023-03-21 | 2023-07-25 | 诺赛联合(北京)生物医学科技有限公司 | 一种干细胞外泌体提取试剂盒及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092771A2 (en) * | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EP2364996B1 (de) * | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimierte FC-Varianten und Verfahren zu ihrer Erzeugung |
JP5215180B2 (ja) * | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Cd19抗体およびその使用法 |
TW201206955A (en) | 2007-11-13 | 2012-02-16 | Evec Inc | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
PE20120591A1 (es) * | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla |
JP5719354B2 (ja) * | 2009-05-27 | 2015-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三重又は四重特異性抗体 |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
EP2776061B1 (de) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispezifische und multivalente bindungsproteine und verwendungen davon |
US9758591B2 (en) * | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
US9732150B2 (en) | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
CN113943366A (zh) * | 2013-06-26 | 2022-01-18 | 努玛医疗技术有限公司 | 新型抗体框架 |
ES2912932T3 (es) * | 2013-07-25 | 2022-05-30 | Cytomx Therapeutics Inc | Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y procedimientos de uso de los mismos |
WO2015058861A1 (en) | 2013-10-25 | 2015-04-30 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
CA2940242A1 (en) | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3237449A2 (de) * | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispezifische antikörper |
JP6640232B2 (ja) * | 2015-02-06 | 2020-02-05 | ユニバーシティ オブ メリーランド,ボルチモア | クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンa及びトキシンbに対する四重特異性の八量体型結合剤及び抗体 |
CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
WO2017049004A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
CN110891650B (zh) * | 2017-06-25 | 2024-06-11 | 西雅图免疫公司 | 制导和导航控制蛋白及其制造和使用方法 |
US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
US12029761B2 (en) * | 2018-03-27 | 2024-07-09 | Systimmune, Inc. | Guidance and Navigation Control proteins and method of making and using thereof |
-
2018
- 2018-06-22 CN CN202310141062.3A patent/CN116041530A/zh active Pending
- 2018-06-22 JP JP2020520429A patent/JP7399852B2/ja active Active
- 2018-06-22 CN CN201880039401.4A patent/CN110831973B/zh active Active
- 2018-06-22 RU RU2020102662A patent/RU2020102662A/ru unknown
- 2018-06-22 US US16/615,122 patent/US11787863B2/en active Active
- 2018-06-22 IL IL313468A patent/IL313468A/en unknown
- 2018-06-22 KR KR1020207002328A patent/KR20200092301A/ko not_active Application Discontinuation
- 2018-06-22 EP EP18825293.6A patent/EP3645049A4/de active Pending
- 2018-06-22 CN CN202310141321.2A patent/CN116199785A/zh active Pending
- 2018-06-22 CN CN202310922275.XA patent/CN116948035A/zh active Pending
- 2018-06-22 WO PCT/US2018/039156 patent/WO2019005639A2/en unknown
- 2018-06-22 CA CA3068045A patent/CA3068045A1/en active Pending
- 2018-06-22 IL IL271257A patent/IL271257B1/en unknown
- 2018-06-22 AU AU2018295118A patent/AU2018295118A1/en active Pending
- 2018-06-22 SG SG11201912864SA patent/SG11201912864SA/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2020530777A (ja) | 2020-10-29 |
RU2020102662A (ru) | 2021-07-27 |
US20220002406A1 (en) | 2022-01-06 |
EP3645049A2 (de) | 2020-05-06 |
CN110831973B (zh) | 2023-08-15 |
IL313468A (en) | 2024-08-01 |
KR20200092301A (ko) | 2020-08-03 |
CN110831973A (zh) | 2020-02-21 |
IL271257B1 (en) | 2024-07-01 |
EP3645049A4 (de) | 2021-06-30 |
CN116199785A (zh) | 2023-06-02 |
WO2019005639A2 (en) | 2019-01-03 |
JP7399852B2 (ja) | 2023-12-18 |
IL271257A (en) | 2020-01-30 |
CN116948035A (zh) | 2023-10-27 |
CA3068045A1 (en) | 2019-01-03 |
US11787863B2 (en) | 2023-10-17 |
CN116041530A (zh) | 2023-05-02 |
AU2018295118A1 (en) | 2020-02-06 |
WO2019005639A3 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271260A (en) | Multispecific antibodies and methods for their preparation and use | |
IL271257A (en) | Multispecific antibodies and methods for their preparation and use | |
EP3645050A4 (de) | Multispezifische antikörper sowie verfahren zu ihrer herstellung und verwendung | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
HUE062927T2 (hu) | Anti-TIGIT ellenanyagok és alkalmazási eljárásaik | |
EP3645742A4 (de) | Anti-ror1-antikörper und verfahren zu ihrer herstellung und verwendung | |
HK1251969A1 (zh) | 抗her2抗體和使用方法 | |
HK1254743A1 (zh) | 新穎抗密封蛋白抗體及使用方法 | |
IL252837B (en) | fcrn antibodies and methods of using them | |
IL275070A (en) | FCRN antibodies and methods of using them | |
EP3313993A4 (de) | Anti-apobec3-antikörper und verfahren zur herstellung und verwendung | |
IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
IL271346A (en) | Bispecific antibodies and methods for their preparation and use | |
RS64530B1 (sr) | Monoklonalna antitela protiv krevetnih stenica i postupci za njihovo pravljenje i upotrebe | |
ZA202002144B (en) | Antibodies and methods of use | |
IL275493A (en) | Antibodies to centrin-1, methods for their preparation and use | |
AU2015901092A0 (en) | PAT-SM3 related antibodies and methods of making and using same | |
AU2014901301A0 (en) | PAT-SM3 related antibodies and methods of making and using same |